Pharmacological treatment of alcohol use disorder. Scientific evidence

Interdisciplinary Study Group CRARL - SITAC - SIPaD - SITD - SIPDip; Simone Macri; Giovanni Laviola; Rosanna Mancinelli

doi:10.1708/2925.29414

Pharmacological treatment of alcohol use disorder. Scientific evidence

Interdisciplinary Study Group CRARL - SITAC - SIPaD - SITD - SIPDip, Simone Macri, Giovanni Laviola, Rosanna Mancinelli

Research output: Contribution to journal › Article › peer-review

Abstract

Pharmacological treatment of alcohol use disorder represents an essential core of the therapeutic project in a multidisciplinary approach. While non-drug treatment is evolving, from a medical perspective few pharmacotherapies are available; in particular acamprosate, naltrexone and more recently nalmefene among anticraving drugs, disulfiram as an antidipsotropic medication. New studies are focusing on off-label drugs. Moreover, scientific evidence has to support any therapeutic indication which should be tailored on patient needs and comorbidity by considering the individual bio-psycho-social profile. Follow-up is essential in order to assess patient compliance to treatment and monitoring outcomes.

Original language	English
Pages (from-to)	123-127
Number of pages	5
Journal	Rivista di Psichiatria
Volume	53
Issue number	3
DOIs	https://doi.org/10.1708/2925.29414
Publication status	Published - Jun 19 2018

Keywords

Acamprosate/therapeutic use
Alcohol Deterrents/therapeutic use
Alcoholism/drug therapy
Baclofen/therapeutic use
Disulfiram/therapeutic use
Drug Evaluation
Humans
Naltrexone/analogs & derivatives
Off-Label Use
Olanzapine/therapeutic use
Ondansetron/therapeutic use
Sertraline/therapeutic use
Sodium Oxybate/therapeutic use
Topiramate/therapeutic use
Varenicline/therapeutic use

Access to Document

10.1708/2925.29414

Fingerprint Dive into the research topics of 'Pharmacological treatment of alcohol use disorder. Scientific evidence'. Together they form a unique fingerprint.

Cite this

@article{2b4b59ad6bf54c878b7c25aeea81b1b1,

title = "Pharmacological treatment of alcohol use disorder. Scientific evidence",

abstract = "Pharmacological treatment of alcohol use disorder represents an essential core of the therapeutic project in a multidisciplinary approach. While non-drug treatment is evolving, from a medical perspective few pharmacotherapies are available; in particular acamprosate, naltrexone and more recently nalmefene among anticraving drugs, disulfiram as an antidipsotropic medication. New studies are focusing on off-label drugs. Moreover, scientific evidence has to support any therapeutic indication which should be tailored on patient needs and comorbidity by considering the individual bio-psycho-social profile. Follow-up is essential in order to assess patient compliance to treatment and monitoring outcomes.",

keywords = "Acamprosate/therapeutic use, Alcohol Deterrents/therapeutic use, Alcoholism/drug therapy, Baclofen/therapeutic use, Disulfiram/therapeutic use, Drug Evaluation, Humans, Naltrexone/analogs & derivatives, Off-Label Use, Olanzapine/therapeutic use, Ondansetron/therapeutic use, Sertraline/therapeutic use, Sodium Oxybate/therapeutic use, Topiramate/therapeutic use, Varenicline/therapeutic use",

author = "{Interdisciplinary Study Group CRARL - SITAC - SIPaD - SITD - SIPDip} and Fabio Attilia and Roberta Perciballi and Claudia Rotondo and Ida Capriglione and Silvia Iannuzzi and Attilia, {Maria Luisa} and Mario Vitali and Giovanni Alessandrini and Scamporrino, {Maria Concetta Marcella} and Marco Fiore and Mauro Ceccanti and Simone Macri and Giovanni Laviola and Rosanna Mancinelli",

year = "2018",

month = jun,

day = "19",

doi = "10.1708/2925.29414",

language = "English",

volume = "53",

pages = "123--127",

journal = "Rivista di Psichiatria",

issn = "0035-6484",

publisher = "Il Pensiero Scientifico Editore s.r.l.",

number = "3",

}

TY - JOUR

T1 - Pharmacological treatment of alcohol use disorder. Scientific evidence

AU - Interdisciplinary Study Group CRARL - SITAC - SIPaD - SITD - SIPDip

AU - Attilia, Fabio

AU - Perciballi, Roberta

AU - Rotondo, Claudia

AU - Capriglione, Ida

AU - Iannuzzi, Silvia

AU - Attilia, Maria Luisa

AU - Vitali, Mario

AU - Alessandrini, Giovanni

AU - Scamporrino, Maria Concetta Marcella

AU - Fiore, Marco

AU - Ceccanti, Mauro

AU - Macri, Simone

AU - Laviola, Giovanni

AU - Mancinelli, Rosanna

PY - 2018/6/19

Y1 - 2018/6/19

N2 - Pharmacological treatment of alcohol use disorder represents an essential core of the therapeutic project in a multidisciplinary approach. While non-drug treatment is evolving, from a medical perspective few pharmacotherapies are available; in particular acamprosate, naltrexone and more recently nalmefene among anticraving drugs, disulfiram as an antidipsotropic medication. New studies are focusing on off-label drugs. Moreover, scientific evidence has to support any therapeutic indication which should be tailored on patient needs and comorbidity by considering the individual bio-psycho-social profile. Follow-up is essential in order to assess patient compliance to treatment and monitoring outcomes.

AB - Pharmacological treatment of alcohol use disorder represents an essential core of the therapeutic project in a multidisciplinary approach. While non-drug treatment is evolving, from a medical perspective few pharmacotherapies are available; in particular acamprosate, naltrexone and more recently nalmefene among anticraving drugs, disulfiram as an antidipsotropic medication. New studies are focusing on off-label drugs. Moreover, scientific evidence has to support any therapeutic indication which should be tailored on patient needs and comorbidity by considering the individual bio-psycho-social profile. Follow-up is essential in order to assess patient compliance to treatment and monitoring outcomes.

KW - Acamprosate/therapeutic use

KW - Alcohol Deterrents/therapeutic use

KW - Alcoholism/drug therapy

KW - Baclofen/therapeutic use

KW - Disulfiram/therapeutic use

KW - Drug Evaluation

KW - Humans

KW - Naltrexone/analogs & derivatives

KW - Off-Label Use

KW - Olanzapine/therapeutic use

KW - Ondansetron/therapeutic use

KW - Sertraline/therapeutic use

KW - Sodium Oxybate/therapeutic use

KW - Topiramate/therapeutic use

KW - Varenicline/therapeutic use

U2 - 10.1708/2925.29414

DO - 10.1708/2925.29414

M3 - Article

C2 - 29912214

VL - 53

SP - 123

EP - 127

JO - Rivista di Psichiatria

JF - Rivista di Psichiatria

SN - 0035-6484

IS - 3

ER -